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Abstract
Background: Senataxin (chromosome 9q34) was recently identified as the causative gene for an
autosomal recessive form of Ataxia (ARCA), termed as Ataxia with Oculomotor Apraxia, type 2
(AOA2) and characterized by generalized incoordination, cerebellar atrophy, peripheral
neuropathy, "oculomotor apraxia" and increased alpha-fetoprotein (AFP). Here, we report a novel
Senataxin mutation in a Cypriot ARCA family.
Methods: We studied several Cypriot autosomal recessive cerebellar ataxia (ARCA) families for
linkage to known ARCA gene loci. We linked one family (909) to the SETX locus on chromosome
9q34 and screened the proband for mutations by direct sequencing.
Results: Sequence analysis revealed a novel c.5308_5311delGAGA mutation in exon 11 of the
SETX gene. The mutation has not been detected in 204 control chromosomes from the Cypriot
population, the remaining Cypriot ARCA families and 37 Cypriot sporadic cerebellar ataxia
patients.
Conclusion: We identified a novel SETX homozygous c.5308_5311delGAGA mutation that co-
segregates with ARCA with cerebellar atrophy and raised AFP.
Background
Autosomal recessive cerebellar ataxias (ARCA) form a
group of heterogeneous disorders characterised by auto-
somal recessive inheritance, cerebellar ataxia and an early
onset of disease, usually before the age of 20 [1]. The so
called Ataxia with Oculomotor Apraxia type 2 was
recently found as the second most frequent ARCA, after
Freidreich's Ataxia in a group of 77 families, most of them
(69%) of French origin [2]. AOA2 has been mapped to
chromosome 9q34 [3,4] and more recently mutations in
the senataxin (SETX) gene were identified in AOA2
patients [5]. Senataxin contains a domain found in super-
family 1 of helicases and is the human ortholog of yeast
Sen1p gene [5]. Autosomal dominant mutations in the
same gene occur in a form of juvenile amyotrophic lateral
sclerosis (ALS4) [6].
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In the late 1980s a cluster of 7 Friedreich's Ataxia families
with 13 affected members was identified in the Cypriot
population and the highest estimated carrier frequency of
1-in-6 to 1-in-7 was reported for two neighbouring vil-
lages in the western part of the island [7]. Since then 16
additional FRDA patients, 13 non-FRDA ARCA families, 1
ADSCA family and 37 sporadic cerebellar ataxia patients
were ascertained in the Cypriot population.
Initial linkage studies of the non-FRDA ARCA families
showed linkage of family 909 to the senataxin locus on
chromosome 9q34. We hereby report the identification of
the second ARCA mutation in the Cypriot population, a
novel SETX deletion. This mutation has not been identi-
fied in 204 normal chromosomes and it has not been
detected in any of the remaining non-FRDA ARCA fami-
lies or sporadic cerebellar ataxia patients in our popula-
tion.
Methods
Subjects and samples
Family 909 was a two-generation, 18-member Greek Cyp-
riot ataxia kindred with 5 affected individuals in one gen-
eration (Figure 1). The parents originate from different
villages 10 Km apart in the Paphos district of Cyprus, and
any traceable relation was excluded. Our study of ataxias
in the Paphos district of Cyprus was approved by the
Cyprus Institute of Neurology and Genetics Ethics Com-
mittee. Written informed consent was obtained from all
participants of the study. Ten members (4 affected) of the
family were examined clinically and brain MRI was per-
formed in the youngest affected individual (II-14) at age
25 years old. The proband (II-2) at the last examination
was a 44-years-old male with a 30 year history of ataxia
(onset at 14 yo). He presented with ataxia, of limb and
trunk movements, truncal titubation, dysarthria, loss of
proprioception and vibration sense, absent deep tendon
reflexes in the lower limbs, bilateral Babinski sign with
pes cavus, spasticity, and scoliosis. There were spontane-
ous random saccadic eye movements at rest. Saccadic eye
movements were present, slow but dysmetric and irregu-
Pedigree of the Cypriot ARCA family 909 Figure 1
Pedigree of the Cypriot ARCA family 909. Haplotypes spanning the SETX locus are shown under the corresponding 
available family members (I-2, II-2, II-3, II-4, II-5, II-7, II-9, II-13, II-14 and II-15). Haplotypes were constructed using the order in 
which the microsatellite marker loci are located in the region; D9S115, D9S1831, D9S179, D9S1830 and D9S164. Affected 
individuals (II-2, II-3, II-9 and II-14) are homozygous for the 5-2-2-1-1 haplotype. PCR and agarose gel electrophoresis based 
mutation detection results are also shown below the corresponding individual. A 105 bp band denotes a normal sequence and 
a 101 bp band denotes a deleted sequence (c.5308_5311delGAGA). Homozygous normal individuals (II-4) have a single 105 bp 
band, homozygous mutant individuals (II-2, II-3, II-9 and II-14) have a single band of 101 bp and heterozygous mutation carrier 
individuals (I-2, II-5, II-13 and II-15) have two bands of 105 and 101 bp.BMC Medical Genetics 2008, 9:28 http://www.biomedcentral.com/1471-2350/9/28
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lar to visual targets in all directions (horizontal and verti-
cal). The patient had diabetes type 2 but no
cardiomyopathy. Overall the clinical presentation of the
affected family members included an age at onset of 8 to
14 years old, slow progressive ataxia of limb and trunk
and eye movements with multidirectional nystagmus,
peripheral neuropathy (clinically), spasticity, Babinski
sign and areflexia. The clinical features of the four partici-
pating patients are included in Table 1. Patient II-3 had a
slightly milder form of the disease with age of onset at the
age of 14, less spasticity in the lower limbs and no pes
cavus deformity. This patient had mild right eye esopho-
ria. Overall, there was no significant variability of the clin-
ical phenotype in this family. Brain MRI of the younger
patient (II-14) showed cerebellar atrophy (Figure 2). Vita-
min E levels were within the normal range but there was
marked increase of AFP levels (Table 1). All patients
refused to undergo electrophysiological studies.
Molecular genetic analyses
Blood samples were obtained after informed consent
from individuals I-2, II-2, II-3, II-4, II-5, II-7, II-9, II-13, II-
14 and II-15. DNA was extracted using standard salting
out procedures. Frataxin (FXN) gene GAA repeat expan-
sion analysis revealed normal range bands in the
proband, thus excluding the diagnosis of FRDA [8]. All
available individuals were genotyped at microsatellite
polymorphic marker loci, spanning candidate ARCA loci
(AVED/TTPA: D8S1696, D8S544; ARSACS/SACS:
D13S232, D13S292; AOA1/APTX: D9S1118 and AOA2/
SETX: D9S115, D9S1831, D9S179, D9S1830, D9S164),
following previously described methodology [9]. Haplo-
types of individuals were constructed manually.
Linkage analyses
Linkage analysis was performed using the LINKAGE pack-
age of programs [10]. Lod scores (Z) were calculated
under an autosomal recessive inheritance model and a
disease allele frequency of 1 in 10,000.
Sequence analysis
Genomic DNA sequencing of the SETX gene was per-
formed on the proband DNA. Primers amplifying the
sequence of the 26 SETX exons were designed by us and
are available upon request. Amplification products were
sequenced in both directions using the CEQ Dye Termina-
tor Cycle Seq. Sequence traces were automatically com-
pared with the normal SETX gene sequence as listed in the
GenBank database (Accession: NT_035014, Region:
1915823..2007712, Version: NT_035014.4, GI:
51467290 of 02 Mar 2006), using the CEQ8000 investiga-
tor software.
Family mutation detection
A 105 bp fragment encompassing the family deletion
mutation sequence was amplified using flanking primers
5'-GGCACAAGAATGGCTCAACT-3' and 5'-AACTTACCT-
GCAAACTCCCAGT-3'. PCR products were run on a 7%
agarose gel. All available family members were initially
screened for the mutation. The proband of each Cypriot
non-FRDA ARCA families and all Cypriot ARCA sporadic
patients were screened for the mutation at a later stage.
Results
Initial linkage analysis of the family to the TTPA, SACS,
APTX and SETX loci revealed probable linkage of the fam-
ily to the SETX locus on chromosome 9q34 with a maxi-
mum lod score of 2.31 at recombination fraction 0 with
microsatellite marker loci D9S115, D9S1831, D9S179
and D9S164 (Table 2). Haplotype analysis further sup-
ported the linkage data (Figure 1) with affected individu-
Brain MRI images of the younger patient (II-14) at age 25  years old, showing cerebellar atrophy Figure 2
Brain MRI images of the younger patient (II-14) at age 25 
years old, showing cerebellar atrophyBMC Medical Genetics 2008, 9:28 http://www.biomedcentral.com/1471-2350/9/28
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als sharing the same haplotype (5-2-2-1-1 for D9S115-
D9S1831-D9S179-D9S1830-D9S164, respectively) in a
homozygous state.
We then performed sequence analysis of the proband (II-
2) DNA sample for the 26 SETX exons and detected a
novel homozygous SETX gene deletion c.5308-
5311delGAGA (Figure 3). This 4 bp deletion causes a
frame shift mutation that results in a Glu-to-Ile change at
amino acid 1770 of the SETX gene and also introduces a
stop codon 15 amino acids further down the new reading
frame (p.Glu1770IlefsX15). We designed a PCR and agar-
ose gel electrophoresis based assay of this mutation in
order to further investigate the remaining affected and
non-affected members of the family and other additional
Cypriot samples. The c.5308-5311delGAGA mutation co-
segregates with the disease haplotype (5-2-2-1-1) of the
family and is found in a homozygous state in all four
affected individuals (Figure 1). It was not detected in any
of 204 normal Cypriot population chromosomes ana-
lysed, thus further supporting the hypothesis that this is
the disease causing mutation in this Cypriot ARCA family.
The above novel SETX mutation is the second ARCA
mutation, after the FRDA GAA repeat expansion, thus far
identified in the Cypriot population. Therefore, we used
the PCR based assay to investigate whether any of the
remaining molecularly undiagnosed Cypriot cerebellar
ataxia patients have this newly identified Cypriot ARCA
mutation. The proband of 12 ARCA families and 37 spo-
radic SCA patients, previously excluded for the FRDA,
SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12,
SCA17 and DRPLA mutations, were analysed for this
novel SETX mutation. The mutation was not detected in
any of the above patients, thus indicating that this is a rare
ARCA mutation in our population.
Discussion
We report a novel SETX gene mutation in a Cypriot ARCA
family. The clinical phenotype of the reported patients is
similar to other reported SETX mutation patients. Overall
the clinical presentation of the affected family members
included an age at onset of 8 to 14 years old, slow progres-
Table 1: Clinical features of family 909 patients. The clinical characteristics of participating patients are presented below.
Clinical feature Patient
II-2 II-3 II-9 II-14
Gender M F F M
Age of onset 14 14 8 8
A t a x i a ++++
D y s a r t h r i a ++++
A b n o r m a l  e y e  m o v e m e n t s ++++
Deep tendon reflexes areflexic areflexic Areflexic areflexic
Spasticity in the lower limbs ++++
Babinski sign + indifferent + +
Pes cavus + - + +
Deep sensation (proprioception and vibration) reduced reduced Reduced reduced
S c o l i o s i s ++++
Muscle weakness in upper limbs distal distal Distal distal
Muscle weakness in lower limbs proximal + distal proximal + distal proximal + distal proximal + distal
Muscle atrophy in upper limbs distal distal distal distal
Muscle atrophy in lower limbs distal distal distal distal
C a r d i o m y o p a t h y ----
Diabetes mellitus + - - -
AFP levels in IU/ml 30.5 29.6 34.0 n/a
MRI signs of cerebellar atrophy n/a n/a n/a +
+ = presence, - = absence, n/a = not available, AFP normal range = < 5.5 IU/ml
Table 2: Linkage analysis data of family 909 to ARCA loci. Two-
point lod score values obtained between the disease in family 909 
and each marker locus are presented.
Locus LOD score values at θ
Gene Marker 0.0 0.01 0.05 0.1 0.2
TTPA D8S1996 -inf. -1.26 -0.58 -0.31 -0.09
D8S544 -inf. -1.74 -0.51 -0.11 0.12
SACS D13S232 -inf. -2.81 -1.45 -0.89 -0.39
D13S292 -inf. -2.81 -1.45 -0.89 -0.39
APTX D9S1118 -inf. -5.12 -2.46 -1.42 -0.56
SETX D9S115 2.31 2.26 2.06 1.81 1.29
D9S1831 2.31 2.26 2.06 1.81 1.29
D9S179 2.31 2.26 2.06 1.81 1.29
D9S1830 2.18 2.14 1.96 1.73 1.24
D9S164 2.31 2.26 2.06 1.81 1.29
-inf. = - infinityBMC Medical Genetics 2008, 9:28 http://www.biomedcentral.com/1471-2350/9/28
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sive ataxia of limb and trunk and eye movements with
multidirectional nystagmus, peripheral neuropathy (clin-
ically), spasticity, Babinski sign and areflexia. No signifi-
cant intrafamilial clinical variability was observed
although one patient (II-3) had a slightly milder form of
the disease. AFP levels were measured in 3 of the 5
patients (Table 1) and all were highly elevated, as charac-
teristically found in AOA2 patients.
Senataxin encodes a ubiquitously expressed protein of
2,677 amino acids that shares similarities with the yeast
Sen1 proteins mainly at the carboxy-terminus conserved
superfamily I DNA/RNA helicase domain spanning
amino acids 1,931 to 2,456 [5,6]. Although the function
of senataxin is poorly understood, it is speculated that,
like the DNA/RNA helicases, it is involved in DNA repair,
replication, recombination, transcription, RNA process-
ing, transcript stability and translation initiation. Evi-
dence that SETX plays a role in the defence against
oxidative DNA damage has recently been reported [11]. In
human cultured cells SETX was found as expected in the
nucleus, but also diffused in the cytoplasm, thus indicat-
ing additional functions of the protein beyond those of
the yeast Sen1p [12]. SETX gene mutations were identified
in autosomal recessive AOA2 [5,13-17], autosomal dom-
inant ALS4 [6] and more recently in autosomal dominant
tremor/ataxia syndrome [18]. Missense mutations have
been identified both in the C-terminus conserved helicase
domain and the N-terminal part of the SETX protein, thus
indicating that other than the helicase regions of the pro-
tein are also important for the pathogenesis of AOA2.
The homozygous c.5308-5311delGAGA mutation is a
frame shift deletion that results in a Glu-to-Ile change at
amino acid 1770 of the SETX gene and also introduces a
stop codon 15 amino acids further down the new reading
frame (p.Glu1770IlefsX15). It is likely that this mutation
most probably results in a truncated protein lacking the c-
terminal helicase domain of the SETX protein. This novel
mutation adds to 30 already known SETX gene mutations
causing AOA2, most of them reported by Fogel et al [16].
Identification of additional AOA2 mutations may con-
tribute towards conclusive genotype/phenotype correla-
tions.
We hereby describe the second ARCA mutation thus far
identified in the Cypriot population after the FRDA GAA
repeat expansion. Absence of this novel mutation from 12
Cypriot ARCA families and 37 sporadic cerebellar ataxia
patients pending molecular diagnosis indicates that fur-
ther genetic heterogeneity of cerebellar ataxia exists in the
Cypriot population. The Cypriot population under study
was 766,400 at the 2005 census; therefore, the frequency
of patients with this novel SETX mutation is estimated to
be 1 in approximately 150,000 of the population.
Although the family excluded any known relation
between the parents, a common ancestor or founder effect
is more likely.
Conclusion
We identified the second ARCA mutation in the Cypriot
population, after the FRDA GAA repeat expansion, a novel
SETX homozygous c.5308_5311delGAGA mutation that
co-segregates with the ataxia phenotype in a Cypriot
ARCA family with 5 affected individuals.
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Sequence analysis data of the SETX gene region Figure 3
Sequence analysis data of the SETX gene region. A: 
amino acid sequence of normal control individual (II-4). B: 
amino acid sequence of the proband (II-2), homozygous for 
the c.5308_5311delGAGA mutation. C: amino acid sequence 
of carrier (I-2), heterozygous for the c.5308_5311delGAGA 
mutation.
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